Ayush Tandon
Partner
DelhiPractice Area
I thrive on being deeply involved in a matter, using a legal, financial and commercial lens, deploying strategic foresight to create innovative solutions and ideas.
Ayush Tandon specialises in Corporate/M&A, Regulatory and White-Collar Crime matters. In addition to being a lawyer, Ayush is a qualified CA and CFA. He has significant experience acting for global clients in cross border fraud and asset recovery matters. Ayush has represented a broad range of multinational and domestic clients across various industries on compliance and regulatory issues and assisted them with internal and external investigations on anti-bribery, anti-corruption, and tax.
WORK HIGHLIGHTS
-
On (i) Its constitutional challenge against a potential ban from acting as an auditor for companies under Section 140(5) of the Companies Act, 2013 and the power to sanction an investigation by the Serious Frauds Investigation Office before the Bombay High Court and the Supreme Court (ii) A regulatory inquiry pertaining to a large matter of alleged financial irregularity
-
On (i) Its disinvestment of ‘Horlicks’ and other Consumer Healthcare nutrition products in India to Unilever (ii) The merger of its Indian listed entity, GlaxoSmithKline Consumer Healthcare with Hindustan Unilever, awarded ‘Deal of the Year’ by India Business Law Journal (2019)
-
On fraud reporting, investigations and whistle-blower issues
-
on a large banking fraud and asset recovery matter
-
On structuring of their entities and various niche issues
-
On important international tax matters
-
On (i) Its constitutional challenge against a potential ban from acting as an auditor for companies under Section 140(5) of the Companies Act, 2013 and the power to sanction an investigation by the Serious Frauds Investigation Office before the Bombay High Court and the Supreme Court (ii) A regulatory inquiry pertaining to a large matter of alleged financial irregularity
-
On (i) Its disinvestment of ‘Horlicks’ and other Consumer Healthcare nutrition products in India to Unilever (ii) The merger of its Indian listed entity, GlaxoSmithKline Consumer Healthcare with Hindustan Unilever, awarded ‘Deal of the Year’ by India Business Law Journal (2019)
-
On fraud reporting, investigations and whistle-blower issues
-
on a large banking fraud and asset recovery matter
-
On structuring of their entities and various niche issues
-
On important international tax matters
-
On (i) Its constitutional challenge against a potential ban from acting as an auditor for companies under Section 140(5) of the Companies Act, 2013 and the power to sanction an investigation by the Serious Frauds Investigation Office before the Bombay High Court and the Supreme Court (ii) A regulatory inquiry pertaining to a large matter of alleged financial irregularity
-
On (i) Its disinvestment of ‘Horlicks’ and other Consumer Healthcare nutrition products in India to Unilever (ii) The merger of its Indian listed entity, GlaxoSmithKline Consumer Healthcare with Hindustan Unilever, awarded ‘Deal of the Year’ by India Business Law Journal (2019)
-
On fraud reporting, investigations and whistle-blower issues
-
on a large banking fraud and asset recovery matter
-
On structuring of their entities and various niche issues
-
On important international tax matters
-
On (i) Its constitutional challenge against a potential ban from acting as an auditor for companies under Section 140(5) of the Companies Act, 2013 and the power to sanction an investigation by the Serious Frauds Investigation Office before the Bombay High Court and the Supreme Court (ii) A regulatory inquiry pertaining to a large matter of alleged financial irregularity
-
On (i) Its disinvestment of ‘Horlicks’ and other Consumer Healthcare nutrition products in India to Unilever (ii) The merger of its Indian listed entity, GlaxoSmithKline Consumer Healthcare with Hindustan Unilever, awarded ‘Deal of the Year’ by India Business Law Journal (2019)
-
On fraud reporting, investigations and whistle-blower issues
-
on a large banking fraud and asset recovery matter
-
On structuring of their entities and various niche issues
-
On important international tax matters
-
On (i) Its constitutional challenge against a potential ban from acting as an auditor for companies under Section 140(5) of the Companies Act, 2013 and the power to sanction an investigation by the Serious Frauds Investigation Office before the Bombay High Court and the Supreme Court (ii) A regulatory inquiry pertaining to a large matter of alleged financial irregularity
-
On (i) Its disinvestment of ‘Horlicks’ and other Consumer Healthcare nutrition products in India to Unilever (ii) The merger of its Indian listed entity, GlaxoSmithKline Consumer Healthcare with Hindustan Unilever, awarded ‘Deal of the Year’ by India Business Law Journal (2019)
-
On fraud reporting, investigations and whistle-blower issues
-
on a large banking fraud and asset recovery matter
-
On structuring of their entities and various niche issues
-
On important international tax matters
-
On (i) Its constitutional challenge against a potential ban from acting as an auditor for companies under Section 140(5) of the Companies Act, 2013 and the power to sanction an investigation by the Serious Frauds Investigation Office before the Bombay High Court and the Supreme Court (ii) A regulatory inquiry pertaining to a large matter of alleged financial irregularity
-
On (i) Its disinvestment of ‘Horlicks’ and other Consumer Healthcare nutrition products in India to Unilever (ii) The merger of its Indian listed entity, GlaxoSmithKline Consumer Healthcare with Hindustan Unilever, awarded ‘Deal of the Year’ by India Business Law Journal (2019)
-
On fraud reporting, investigations and whistle-blower issues
-
on a large banking fraud and asset recovery matter
-
On structuring of their entities and various niche issues
-
On important international tax matters
-
On (i) Its constitutional challenge against a potential ban from acting as an auditor for companies under Section 140(5) of the Companies Act, 2013 and the power to sanction an investigation by the Serious Frauds Investigation Office before the Bombay High Court and the Supreme Court (ii) A regulatory inquiry pertaining to a large matter of alleged financial irregularity
-
On (i) Its disinvestment of ‘Horlicks’ and other Consumer Healthcare nutrition products in India to Unilever (ii) The merger of its Indian listed entity, GlaxoSmithKline Consumer Healthcare with Hindustan Unilever, awarded ‘Deal of the Year’ by India Business Law Journal (2019)
-
On fraud reporting, investigations and whistle-blower issues
-
on a large banking fraud and asset recovery matter
-
On structuring of their entities and various niche issues
-
On important international tax matters
-
On (i) Its constitutional challenge against a potential ban from acting as an auditor for companies under Section 140(5) of the Companies Act, 2013 and the power to sanction an investigation by the Serious Frauds Investigation Office before the Bombay High Court and the Supreme Court (ii) A regulatory inquiry pertaining to a large matter of alleged financial irregularity
-
On (i) Its disinvestment of ‘Horlicks’ and other Consumer Healthcare nutrition products in India to Unilever (ii) The merger of its Indian listed entity, GlaxoSmithKline Consumer Healthcare with Hindustan Unilever, awarded ‘Deal of the Year’ by India Business Law Journal (2019)
-
On fraud reporting, investigations and whistle-blower issues
-
on a large banking fraud and asset recovery matter
-
On structuring of their entities and various niche issues
-
On important international tax matters
-
On (i) Its constitutional challenge against a potential ban from acting as an auditor for companies under Section 140(5) of the Companies Act, 2013 and the power to sanction an investigation by the Serious Frauds Investigation Office before the Bombay High Court and the Supreme Court (ii) A regulatory inquiry pertaining to a large matter of alleged financial irregularity
-
On (i) Its disinvestment of ‘Horlicks’ and other Consumer Healthcare nutrition products in India to Unilever (ii) The merger of its Indian listed entity, GlaxoSmithKline Consumer Healthcare with Hindustan Unilever, awarded ‘Deal of the Year’ by India Business Law Journal (2019)
-
On fraud reporting, investigations and whistle-blower issues
-
on a large banking fraud and asset recovery matter
-
On structuring of their entities and various niche issues
-
On important international tax matters
-
On (i) Its constitutional challenge against a potential ban from acting as an auditor for companies under Section 140(5) of the Companies Act, 2013 and the power to sanction an investigation by the Serious Frauds Investigation Office before the Bombay High Court and the Supreme Court (ii) A regulatory inquiry pertaining to a large matter of alleged financial irregularity
-
On (i) Its disinvestment of ‘Horlicks’ and other Consumer Healthcare nutrition products in India to Unilever (ii) The merger of its Indian listed entity, GlaxoSmithKline Consumer Healthcare with Hindustan Unilever, awarded ‘Deal of the Year’ by India Business Law Journal (2019)
-
On fraud reporting, investigations and whistle-blower issues
-
on a large banking fraud and asset recovery matter
-
On structuring of their entities and various niche issues
-
On important international tax matters
-
On (i) Its constitutional challenge against a potential ban from acting as an auditor for companies under Section 140(5) of the Companies Act, 2013 and the power to sanction an investigation by the Serious Frauds Investigation Office before the Bombay High Court and the Supreme Court (ii) A regulatory inquiry pertaining to a large matter of alleged financial irregularity
-
On (i) Its disinvestment of ‘Horlicks’ and other Consumer Healthcare nutrition products in India to Unilever (ii) The merger of its Indian listed entity, GlaxoSmithKline Consumer Healthcare with Hindustan Unilever, awarded ‘Deal of the Year’ by India Business Law Journal (2019)
-
On fraud reporting, investigations and whistle-blower issues
-
on a large banking fraud and asset recovery matter
-
On structuring of their entities and various niche issues
-
On important international tax matters